Company Profile

ChemDiv Inc (AKA: Chemical Diversity Labs Inc)
Profile last edited on: 2/16/2017      CAGE: 3YJW6      UEI: WZKETC8NCBF1

Business Identifier: Chemistry on demand
Year Founded
1990
First Award
2004
Latest Award
2007
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6605 Nancy Ridge Drive
San Diego, CA 92121
   (858) 794-4860
   chemdiv@chemdiv.com
   www.chemdiv.com
Location: Multiple
Congr. District: 51
County: San Diego

Public Profile

ChemDiv, a global Contract Research Organization (CRO), offers Integrated Discovery outSource™ solutions that cover a complete range of disciplines from medicinal chemistry to clinical development needed to bring new drugs from target to market. The firm is a global chemistry-driven contract research organization focused on scientific innovation to deliver services that meet the drug discovery needs of its partners. Drawing on a long heritage in small-molecule chemistry research, a dedicated and personal approach to collaborative research and development as well as world class personnel and physical resources, ChemDiv provides partners with access to Discovery outSource™ a full service drug discovery offering encompassing synthetic chemistry; medicinal chemistry, diverse & focused screening libraries, global logistics and lead discovery. The firms is staffed by a multi-disciplinary team of research scientists, technical support and customer service personnel with facilities in San Diego, USA, and Moscow, Russia.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 1 NIH $100,000
Project Title: Discovery of Small Molecule hACC2 Inhibitors for Treatment of Obesity
2007 2 NIH $850,086
Project Title: Identification of Novel ACTH small molecule Antagonists
2004 1 NIH $100,000
Project Title: Drug Discovery for Treatment of Obesity

Key People / Management

  Nikolay Savchuk -- President & CEO

  Bill Farley -- Senior Director Business Development,

  Piotr Gornicki

  Alena Ivachtchenko -- Business Development Executive

  Rouslan Mitchenko -- Director Business Development

  Ilya Okun -- Chief Technology Officer

Company News

There are no news available.